Small Cell Lung Cancer in 2026: Consolidation IO Is Standard, Tarlatamab Has Full Approval, and the Maintenance Era Has Arrived

Introduction: A Disease That Is Finally Moving

For decades, small cell lung cancer (SCLC) stubbornly resisted progress. Platinum-etoposide chemotherapy was established as the backbone of frontline therapy in the 1970s, and the median overall survival for extensive-stage disease barely budged for forty years. The addition of checkpoint inhibitors to frontline platinum-etoposide in 2018 and 2019 was real progress, marking the first survival benefit in years. However, the benefit was modest, and the immunotherapy tail remained frustratingly small.

The landscape in 2026 looks meaningfully different. Consolidation immunotherapy after chemoradiation has become the new standard in limited-stage disease. Tarlatamab, a DLL3-targeting bispecific T-cell engager, has earned full FDA approval in the second-line setting based on robust phase 3 data. Lurbinectedin plus atezolizumab has become the first approved maintenance chemotherapy option in extensive-stage disease. There is now also a wave of antibody-drug conjugates currently advancing through late-stage trials with promising early efficacy. None of this cures SCLC, but the treatment menu is substantially richer than it was even two years ago.

Limited-Stage SCLC: ADRIATIC Changes Standard of Care

Until 2024, the standard approach for limited-stage SCLC after chemoradiation was observation. The ADRIATIC trial changed that.

ADRIATIC enrolled patients with stages 1 through 3 limited-stage SCLC, including inoperable stage 1 and 2, who had not progressed after concurrent platinum-etoposide and radiation. Patients were randomized to consolidation durvalumab (1,500 mg IV every 4 weeks for up to 2 years) versus placebo, with a third arm of durvalumab plus tremelimumab. The primary analysis compared durvalumab to placebo.

Results: Median overall survival 56 months with durvalumab versus 33 months with placebo (hazard ratio 0.73). This is a strikingly large absolute difference for a consolidation strategy. The Kaplan-Meier curves separate clearly and stay separated. FDA granted approval in December 2024.

The pneumonitis concern in this population is particularly important given that patients have already received thoracic radiation. Reassuringly, radiation pneumonitis rates were comparable between arms. Immune-related pneumonitis was modestly higher with durvalumab (10.7% vs 6%), but there were no excess pneumonitis deaths.

Every patient with limited-stage SCLC who completes chemoradiation without progression should now be offered consolidation durvalumab. This is no longer a question.

Why Concurrent IO with Radiation Doesn't Work: NRG-LU005

While ADRIATIC established consolidation immunotherapy after chemoradiation, the NRG-LU005 trial asked a different question: does adding atezolizumab concurrently with chemoradiation (and continuing as consolidation) improve outcomes?

The answer is no. NRG-LU005 enrolled limited-stage patients, randomized them at the start of cycle 2 to add atezolizumab concurrently with platinum-etoposide and radiation, and continued atezolizumab after radiation. The overall survival curves overlapped with no benefit seen with the addition of atezolizumab. Pneumonitis rates were slightly higher with atezolizumab but without concerning mortality.

These results seen in SCLC are consistent with the PACIFIC-2 trial result in NSCLC; adding IO concurrently with radiation does not add benefit over giving it sequentially after radiation completion. The take-home for limited-stage SCLC is straightforward: complete chemoradiation first, then start durvalumab as consolidation.

PCI: A Controversy Moving Toward Resolution

Prophylactic cranial irradiation (PCI) has historically been offered to limited-stage SCLC patients based on data predating routine brain MRI surveillance. In current practice, brain MRI surveillance can detect brain metastases earlier rather than waiting until symptomatic presentation, and the benefit-risk calculation for whole-brain radiation has shifted. Most patients, when counseled on both options, prefer brain MRI surveillance.

The MAVERICK trial is directly comparing PCI to no PCI with brain MRI surveillance occurring in both arms, in both limited and extensive-stage patients. The primary endpoint is overall survival and results are still pending. Until that data arrives, the role of PCI remains controversial, and careful discussion with patients about their preferences is appropriate.

Extensive-Stage Frontline: Atezo or Durva, Your Choice

IMpower133 (atezolizumab) and CASPIAN (durvalumab), both adding a checkpoint inhibitor to platinum-etoposide, are the approved frontline options for extensive-stage SCLC. The trials differ in design details; CASPIAN allowed cisplatin and up to 6 cycles, while IMpower133 was placebo-controlled, but the survival curves are strikingly similar. PD-L1 status does not predict benefit for either regimen. Both are appropriate; selection is based on institutional familiarity, access, and individual patient factors.

Lurbinectedin Maintenance: A New First

Approximately 50% of extensive-stage SCLC patients who complete induction chemotherapy never makes it to second-line therapy. They progress and decline too quickly. Moving effective agents earlier, into the maintenance phase, has therefore become a priority.

The IMforte trial enrolled patients who had not progressed after 4 cycles of standard carboplatin-etoposide plus atezolizumab, then randomized them to maintenance with lurbinectedin (3.2 mg/m² every 3 weeks) plus atezolizumab versus atezolizumab alone.

Results: PFS was 5.4 months with lurbinectedin plus atezolizumab versus 2.1 months with atezolizumab alone (hazard ratio 0.54), measured from the time of maintenance randomization. Overall survival also showed benefit with lurbnectidin added to atezolizumab. Based upon these positive results, the FDA approved lurbinectedin plus atezolizumab for extensive-stage SCLC maintenance in October 2025.

Of note, the added toxicity with lurbinectidin is primarily chemotherapy-related: grade 3 or higher adverse events 38% versus 22%. There were no unexpected toxicities, though increased rates of cytopenias, fatigue, and nausea does add burden to patients and requires honest counseling.

Tarlatamab in the Maintenance Setting: DeLLphi-303 Signal

DeLLphi-303 was a non-randomized phase 1b study examining tarlatamab (a DLL3 × CD3 bispecific T-cell engager) as first-line maintenance after 4 to 6 cycles of platinum-etoposide plus anti-PD-L1. Patients could switch between anti-PD-L1 agents. Despite this being an early non-randomized study, the preliminary overall survival signal is remarkable: OS exceeding 2 years in the maintenance cohort, which is essentially unprecedented in extensive-stage SCLC.

Tarlatamab's CRS and ICANS profile in the maintenance setting was manageable: CRS occurred but was mostly low grade; ICANS occurred in approximately 6% of patients, all early onset and managed with supportive care.

The confirmatory DeLLphi-305 phase 3 trial, comparing tarlatamab plus durvalumab versus durvalumab maintenance alone, is the most anticipated trial result in SCLC. Enrollment has completed at approximately 550 patients worldwide; data are expected later this year.

Tarlatamab Second-Line: Full Approval Based on DeLLphi-304

DeLLphi-304 was the confirmatory phase 3 trial comparing tarlatamab to investigator-choice chemotherapy (predominantly topotecan) in patients with extensive-stage SCLC who had progressed after platinum-based chemotherapy.

Results: OS 13.6 months with tarlatamab versus 8.3 months with chemotherapy (hazard ratio 0.60), providing a clinically meaningful survival benefit seen with tarlatamab. Grade 3 or higher treatment-related adverse events were dramatically lower with tarlatamab (27% vs 62%). In November 2025, FDA granted full approval for tarlatamab in this setting, upgrading from the accelerated approval granted one year earlier.

A clinical case from this conference provided a real world illustration of tarlatamab's efficacy: a 66-year-old woman with extensive-stage SCLC with liver metastases achieved a complete metabolic response to induction carbo-etoposide with atezolizumab. Subsequently, she developed oligoprogression in a mediastinal lymph node as well as new brain metastases. She received radiation to her brain metastases and underwent chemoradiation to the lymph node recurrence. After completion of chemoradiation, extrapolating from the ADRIATIC data, she went on to receive additional consolidation durvalumab. After several months, she eventually developed new liver and new brain metastases and was started on tarlatamab. She experienced grade 2 CRS and grade 2 ICANS with the first two doses, both resolving with steroids. By the third cycle, she tolerated treatment well without significant side effects. Subsequent PET/CT imaging demonstrated complete metabolic response. This case illustrates both the efficacy potential of tarlatamab and the predictability of early-cycle CRS/ICANS that resolves with management.

Tarlatamab is now the preferred second-line option for extensive-stage SCLC after platinum-based chemotherapy. The safety profile is better than chemotherapy, and the survival benefit is now established compared to other chemotherapy options in this setting.

ADC Pipeline: B7H3, DLL3, and TROP2

Three ADCs show meaningful activity in SCLC:

I-Dxd (B7-H3-targeting ADC): IDLung01 phase 2 trial, 137 patients; overall response rate approaching 50%; duration of response approximately 5 months; ILD in approximately 12% of patients. FDA priority review is underway. A phase 3 trial (IDLung01-study) is enrolling.

ABV-706 (DLL3-targeting ADC): Phase 1, approximately 80 patients; ORR approaching 60%, including patients who have progressed on tarlatamab. Preliminary combination data with a novel PD-1 inhibitor versus platinum chemotherapy in the frontline setting are being presented at ASCO 2026.

Sacituzumab govitecan (TROP2 ADC): Phase 2, 43 patients; ORR approximately 42%. Phase 3 ongoing versus topotecan.

The preliminary DLL3 ADC data are particularly notable: DLL3-targeting via an ADC mechanism appears to retain activity after tarlatamab failure, suggesting these two DLL3-directed approaches are not cross-resistant.

Transcriptional Subtypes: The SWOG-PRISM Study

SCLC is not biologically uniform. Research has identified distinct transcriptional subtypes (SCLC-A, SCLC-N, SCLC-P, SCLC-I) with different molecular vulnerabilities. The SWOG-PRISM study is incorporating these subtypes into a novel biomarker driven clinical trial design, randomizing patients to different maintenance therapeutic approaches (PARP inhibitor plus IO, ATR inhibitor, or NK activator) based upon transcriptional subtype. This represents the beginning of precision oncology in SCLC, a disease that has historically been treated as a single entity.

For Patients

If you have been diagnosed with small cell lung cancer, the treatment options available in 2026 are substantially better than they were just a few years ago. For limited-stage disease, a new drug called durvalumab given after chemotherapy and radiation has been shown to more than double median survival compared to chemotherapy and radiation alone. For extensive-stage disease that has returned after initial treatment, tarlatamab is now the preferred second-line treatment, offering better survival and a more tolerable side-effect profile than chemotherapy. Ask your oncologist about these options, and ask whether any clinical trials, including studies of new antibody-drug conjugate treatments, might be appropriate for your situation.

Key Takeaways

  • ADRIATIC: consolidation durvalumab after chemoradiation in limited-stage SCLC; OS 56 vs 33 months (HR 0.73); FDA approved December 2024; now standard for all eligible patients.
  • NRG-LU005: atezolizumab concurrent with chemoradiation, negative trial; no benefit; confirms sequential (not concurrent) IO is the right approach.
  • PCI: controversial; MAVERICK trial comparing PCI vs MRI surveillance underway; most patients prefer surveillance.
  • IMforte: lurbinectedin + atezolizumab maintenance; PFS HR 0.54; OS benefit; FDA approved October 2025; grade 3/4 AEs 38% vs 22%.
  • DeLLphi-303: tarlatamab first-line maintenance signal, OS exceeding 2 years (extraordinary for extensive stage); DeLLphi-305 phase 3 results are awaited.
  • DeLLphi-304: tarlatamab vs chemo second-line; OS 13.6 vs 8.3 months (HR 0.60); full FDA approval November 2025; grade 3+ AEs 27% vs 62% favoring tarlatamab.
  • ADC pipeline: I-Dxd B7-H3 (50% ORR, priority review); ABBV-706 DLL3 (60% ORR including post-tarlatamab); sacituzumab govitecan TROP2 (42% ORR).
  • SWOG-PRISM: first transcriptional subtype-guided clinical trial in SCLC; PARP inhibitor + IO, ATR inhibitor, or NK activator maintenance arms.

References

  1. ADRIATIC trial. Durvalumab consolidation in limited-stage SCLC. New England Journal of Medicine, 2024. FDA approval December 2024.
  2. NRG-LU005. Atezolizumab with chemoradiation in limited-stage SCLC. Presented at ASTRO, 2024.
  3. IMpower133. Atezolizumab plus platinum-etoposide in extensive-stage SCLC. New England Journal of Medicine, 2018.
  4. CASPIAN trial. Durvalumab plus platinum-etoposide in extensive-stage SCLC. Lancet, 2019.
  5. IMforte trial. Lurbinectedin plus atezolizumab maintenance in extensive-stage SCLC. Presented at ASCO, 2025. FDA approval October 2025.
  6. DeLLphi-303. Tarlatamab first-line maintenance in SCLC. Presented at World Lung, 2025.
  7. DeLLphi-304. Tarlatamab vs chemotherapy in previously treated SCLC. New England Journal of Medicine, 2025. FDA full approval November 2025.
  8. I-Dxd (B7-H3 ADC) in SCLC. IDLung01 phase 2. FDA priority review 2025-2026.
  9. ABBV-706 (DLL3 ADC) in SCLC. Phase 1 data, 2025-2026.
  10. Das M. "Advances in SCLC." Presented at the 2026 San Francisco Lung Cancer Conference, San Francisco, CA, May 2026.